P53 accumulation in primary breast cancer: A comparison between immunohistochemistry and a novel luminometric immunoassay

Tumor Biology

Volumn 19, Issue 1, 1997, Pages 12-18

  Bombardieri, Emilio ^a   Seregni, Ettore ^a   Daidone, Maria Grazia ^a   Benini, Elvira ^a   Massaron, Simonetta ^a   Ferrari, Leonardo ^a   Di Fronzo, Giovanni ^a   Silvestrini, Rosella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Immunohistochemistry; Luminometric assay; p53

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ACCURACY; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LUMINESCENCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0031471451     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029970     Document Type: Article

References (16)

1. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-708.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253: 49-53.
3. Lane DP: p53, guardian of the genome. Nature 1992;358:15-16.
4. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR: Problems with p53 immunohistochemical staining: The effect of fixation and variation in the methods of evaluation. Br J Cancer 1994;69:26-31.
5. p53 in tumour pathology: Can we trust immunocytochemistry? (editorial). J Pathol 1992;166:329-330.
6. Silvestrini R, Rao S, Benini E, Daidone MG, Pilotti S: Immunohistochemical detection of p53 in clinical breast cancer: A look at methodologic approaches. J Natl Cancer Inst 1995;87:1020.
7. 3 H]-thymidine labelling index in breast cancer. Cell Prolif 1991;21: 437-445.
8. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 1989;25:1165-1171.
9. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
10. Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred DC, McGuire WL: Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993;26:225-235.
11. Silvestrini R, Benin E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996;14:1604-1610.
12. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1: 1029-1034.
13. Borg A, Lennerstrand J, Stenmark-Askmalm M, Ferno M, Brisfors A, Ohrvik A, Stal O, Killander D, Lane D, Brundell J: Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 1995;71:1013-1017.
14. de Witte HH, Foekens JA, Lennerstrand J, Smid M, Look MP, Klijn JGM, Benraad TJ, Berns EMJJ: Prognostic significance of TP53 accumulation in human primary breast cancer: Comparison between a rapid quantitative immunoassay and SSCP analysis Int J Cancer 1996;69:125-130.
15. Levesque MA, Diamandis EP, Yu H, Sutherland DJA: Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Res Treat 1994;30:179-195.
16. Silvestrini R, Veneroni S, Benini E, Daidone MG, Luisi A, Leutner M, Maucione A, Kenda R, Zucah R, Veronesi U: Expression of p53, GST-π and bcl-2 and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 1997;89: 639-645.